Commonalities and differences in ECT-induced gray matter volume change between depression and schizophrenia
Hirotsugu Kawashima; Shimpei Yamasaki; Manabu Kubota; Masaaki Hazama; Yasutaka Fushimi; Jun Miyata; Toshiya Murai; Taro Suwa
NeuroImage: Clinical, 2023年05月, 査読有り, 最終著者
【今,あらためて考えるうつ病の診断と治療】治療抵抗性うつ病の見立てと治療 今後の展望
諏訪 太朗
臨床精神医学, 2023年01月, 招待有り, 筆頭著者
Information flow and dynamic functional connectivity during electroconvulsive therapy in patients with depression
Yusuke Kyuragi; Naoya Oishi; Shimpei Yamasaki; Masaaki Hazama; Jun Miyata; Mami Shibata; Hironobu Fujiwara; Yasutaka Fushimi; Toshiya Murai; Taro Suwa
Journal of Affective Disorders, 2023年02月, 最終著者
An Online Survey About Electroconvulsive Therapy in Japan During the COVID-19 Pandemic: Comparison of Early and Recent Stages.
Risa Hirata; Hirotsugu Kawashima; Takashi Tsuboi; Ken Wada; Minoru Takebayashi; Taro Suwa
Neuropsychiatric disease and treatment, 2022年, 最終著者, 責任著者
A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project.
Prescription patterns in patients with schizophrenia in Japan: First‐quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project
Improvement of psychiatrists’ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study
Neuropsychiatric Disease and Treatment, 2018年02月21日, 査読有り
Transethnic Replication Study to Assess the Association Between Clozapine-Induced Agranulocytosis/Granulocytopenia and Genes at 12p12.2 in a Japanese Population.